Biosketch / Results /

Douglas Dieterich

Adjunct Professor, Department of Medicine

Contact Info

212/241-4299
Douglas.Dieterich@nyumc.org

Education

1978-1979 — NYU Medical Center, Internship
1979-1981 — NYU Medical Center (Medicine), Residency Training
1979-1981 — NYU Medical Center, Residency Training
1981-1983 — NYU Medical Center (Gastroenterology), Clinical Fellowships

Research Summary

Spector, S., Weingeist, T., Pollard, R.B., et al. A randomized controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J. Infect. Dis. 1993; 168:557-560.

Dieterich D.T., Poles, M.A., Lew, E.A., et al. Concurrentl use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J. Infect. Dis. 1993; 167: 1184-1188.

Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. 4. Visual Outcomes. Ophthalmology. 1994; 101: 1250-1261.

Studies of Ocular complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial-3. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch. Int. Med. 1995;155: 65-74.

Studies of Ocular complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Foscarnet-GanciclovirCytomegalovirus Retinitis Trial-4. Visual outcomes. Ophthalmology.1994; 101: 1250-1261.

Department of Medicine Faculty Listing

Research Interests

Douglas T. Dieterich, M.D.

No effect of proton pump inhibitor (PPI) use on SVR with ledipasvir/sofosbuvir (LDV/SOF): Realworld data from 2034 genotype 1 patients in the trio network
Afdhal, N; Bacon, B; Curry, M; Dieterich, D; Flamm, S; Guest, L; Kowdley, K; Lee, Y; Tsai, N; Younossi, Z. No effect of proton pump inhibitor (PPI) use on SVR with ledipasvir/sofosbuvir (LDV/SOF): Realworld data from 2034 genotype 1 patients in the trio network [Meeting Abstract]. Journal of hepatology. 2016 April 2016;64(2):S222-S222 (2152732)

Effectiveness of 12 or 24 week LDV/SOF and 12 week LDV/SOF+RBV in treatment-experienced patients with cirrhotic, genotype 1 hepatitis C: Real-world experience from the trio network
Curry, M; Bacon, B; Dieterich, D; Flamm, S; Guest, L; Kowdley, K; Lee, Y; Tsai, N; Younossi, Z. Effectiveness of 12 or 24 week LDV/SOF and 12 week LDV/SOF+RBV in treatment-experienced patients with cirrhotic, genotype 1 hepatitis C: Real-world experience from the trio network [Meeting Abstract]. Value in health. 2016 May 2016;19(3):A312-A313 (2161322)

Effectiveness of 8 or 12 week LDV/SOF in treatment-naive patients with non-cirrhotic, genotype 1 hepatitis C: Real-world experience from the trio network
Curry, M; Bacon, B; Dieterich, D; Flamm, S; Guest, L; Kowdley, K; Lee, Y; Tsai, N; Younossi, Z. Effectiveness of 8 or 12 week LDV/SOF in treatment-naive patients with non-cirrhotic, genotype 1 hepatitis C: Real-world experience from the trio network [Meeting Abstract]. Value in health. 2016 May 2016;19(3):A313-A313 (2161312)

Real-world Sustained Virologic Response Rates of Sofosbuvir-containing Regimens in Patients Coinfected with Hepatitis C and HIV
Del Bello, David; Cha, Agnes; Sorbera, Maria; Bichoupan, Kian; Levine, Calley; Doyle, Erin; Harty, Alyson; Patel, Neal; Ng, Michel; Gardenier, Donald; Odin, Joseph; Schiano, Thomas D; Fierer, Daniel S; Berkowitz, Leonard; Perumalswami, Ponni V; Dieterich, Douglas T; Branch, Andrea D. Real-world Sustained Virologic Response Rates of Sofosbuvir-containing Regimens in Patients Coinfected with Hepatitis C and HIV. Clinical infectious diseases. 2016 Mar 1;62(12):1497-1504 (2046262)

Ledipasvir/sofosbuvir+/-ribavirin in patients co-infected with HCV and HIV: Real-world heterogeneous population from the trio network
Dieterich, D; Bacon, B; Curry, M; Flamm, S; Guest, L; Kowdley, K; Lee, Y; Tsai, N; Younossi, Z; Afdhal, N. Ledipasvir/sofosbuvir+/-ribavirin in patients co-infected with HCV and HIV: Real-world heterogeneous population from the trio network [Meeting Abstract]. Journal of hepatology. 2016 April 2016;64(2):S756-S757 (2152712)